Targeted Delivery of Retinoid Compounds to the Sebaceous Glands
    25.
    发明申请
    Targeted Delivery of Retinoid Compounds to the Sebaceous Glands 审中-公开
    维甲酸化合物靶向递送到皮脂腺

    公开(公告)号:US20120328670A1

    公开(公告)日:2012-12-27

    申请号:US13486137

    申请日:2012-06-01

    摘要: Disclosed herein are topical dermal compositions comprising particles, wherein the particles comprisea) a biodegradable polymer, andb) a retinoid selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein the particles have an average diameter between 0.1 μm and 10 μm, and wherein the variables are as defined in the specification. The compositions are useful for treating a condition associated with excess sebum production.

    摘要翻译: 本文公开了包含颗粒的局部皮肤组合物,其中所述颗粒包含a)生物可降解聚合物,和b)选自以下的类视色素:或其药学上可接受的盐,其中所述颗粒的平均直径为0.1μm至10μm μm,并且其中变量如说明书中所定义。 组合物可用于治疗与过量皮脂生成相关的病症。

    Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
    27.
    发明申请
    Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists 有权
    使用过氧化物酶体增殖物激活受体三角体拮抗剂治疗眼部疾病

    公开(公告)号:US20120136041A1

    公开(公告)日:2012-05-31

    申请号:US13281290

    申请日:2011-10-25

    摘要: The present invention provides novel agents, expression constructs, compositions and methods useful for treating an ocular disease associated with unwanted PPARδ activity through the modulation of PPARδ expression. The PPARδ interference RNA (iRNA) agents, expression constructs encoding such agents, and compositions comprising such agents or constructs are directed against RNA molecules encoding PPARδ. The methods comprise treating an ocular disease associated with unwanted PPARδ activity in a patient in need thereof by administering an effective amount of a pharmaceutical composition comprising a PPARδ iRNA agent or expression construct encoding such agent to the patient to reduce a symptom associated with unwanted PPARδ activity in the patient.

    摘要翻译: 本发明提供了通过调节PPARδ表达来治疗与不想要的PPARδ活性相关的眼部疾病的新型药物,表达构建体,组合物和方法。 PPARδ干扰RNA(iRNA)试剂,编码这些试剂的表达构建体和包含这些试剂或构建体的组合物针对编码PPARδ的RNA分子。 所述方法包括通过向患者施用有效量的包含PPARδiRNA试剂或编码该试剂的表达构建体的药物组合物来减少与不需要的PPARδ活性相关的症状来治疗与有需要的患者相关的不需要的PPARδ活性的眼部疾病 在病人身上